<DOC>
	<DOCNO>NCT00290030</DOCNO>
	<brief_summary>To assess efficacy alfuzosin 10mg OD management acute urinary retention associate BPH . To assess safety alfuzosin population health care consumption .</brief_summary>
	<brief_title>ALFAURUS : A DB Randomized Parallel Group Study Alfuzosin 10mg OD v Placebo Management AUR Patients With 1st Episode Due BPH</brief_title>
	<detailed_description>Double-blind , placebo control , randomize Multicenter , Phase III study compare 2 parallel group ( alfuzosin 10mg OD placebo ) patient first episode acute urinary retention relate BPH.The acute episode manage catheterization study drug treatment 2 3 day , follow active void trial ass patient ' ability void catheter removal . Those patient successfully void continue randomize treatment total treatment duration 6 month . For patient prematurely withdraw study , post-study ( clinic phone ) visit perform collection health care consumption data .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Urinary Retention</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Male age 50 year Having give write consent Presenting first episode painful acute urinary retention relate BPH With catheterized urine volume mL mL time retention Associated urological disease / trouble ( e.g . infection surgery prostate , urinary retention f neurogenic origin Iatrogenic cause urinary retention</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>acute urinary retention</keyword>
	<keyword>International Prostate Symptom Score ( IPSS )</keyword>
</DOC>